Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) CFO Sells $31,661.01 in Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) CFO Latha Vairavan sold 1,341 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $23.61, for a total transaction of $31,661.01. Following the sale, the chief financial officer owned 86,413 shares of the company’s stock, valued at $2,040,210.93. This trade represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Latha Vairavan also recently made the following trade(s):

• On Monday, March 2nd, Latha Vairavan sold 2,853 shares of Arcutis Biotherapeutics stock. The shares were sold at an average price of $25.18, for a total transaction of $71,838.54.

Arcutis Biotherapeutics Stock Up 2.5%

NASDAQ ARQT opened at $21.17 on Friday. The company has a current ratio of 2.68, a quick ratio of 2.99 and a debt-to-equity ratio of 0.54. Arcutis Biotherapeutics, Inc. has a 1-year low of $12.72 and a 1-year high of $31.77. The company has a 50 day moving average of $23.65 and a 200-day moving average of $25.77. The company has a market cap of $2.65 billion, a price-to-earnings ratio of -705.43 and a beta of 1.58.

Arcutis Biotherapeutics (NASDAQ:ARQT) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.07). Arcutis Biotherapeutics had a negative net margin of 0.57% and a negative return on equity of 1.41%. The business had revenue of $105.40 million during the quarter, compared to analyst estimates of $103.68 million. On average, equities research analysts expect that Arcutis Biotherapeutics, Inc. will post 0.18 earnings per share for the current fiscal year.

Analyst Ratings Changes

ARQT has been the topic of a number of recent analyst reports. Wall Street Zen cut shares of Arcutis Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research note on Friday, March 27th. HC Wainwright lifted their price objective on shares of Arcutis Biotherapeutics from $30.00 to $34.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Mizuho decreased their price objective on shares of Arcutis Biotherapeutics from $37.00 to $35.00 and set an “outperform” rating on the stock in a research note on Monday, March 2nd. Finally, Guggenheim lifted their price objective on shares of Arcutis Biotherapeutics from $34.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $34.00.

Institutional Trading of Arcutis Biotherapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Focus Partners Wealth grew its stake in shares of Arcutis Biotherapeutics by 0.8% during the third quarter. Focus Partners Wealth now owns 65,196 shares of the company’s stock worth $1,237,000 after buying an additional 490 shares during the last quarter. Arizona State Retirement System grew its stake in shares of Arcutis Biotherapeutics by 1.8% during the third quarter. Arizona State Retirement System now owns 31,685 shares of the company’s stock worth $597,000 after buying an additional 568 shares during the last quarter. Schroder Investment Management Group grew its stake in shares of Arcutis Biotherapeutics by 1.1% during the fourth quarter. Schroder Investment Management Group now owns 57,136 shares of the company’s stock worth $1,604,000 after buying an additional 594 shares during the last quarter. AlphaQuest LLC grew its stake in shares of Arcutis Biotherapeutics by 5.7% during the third quarter. AlphaQuest LLC now owns 12,603 shares of the company’s stock worth $238,000 after buying an additional 682 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its stake in shares of Arcutis Biotherapeutics by 124.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,261 shares of the company’s stock worth $37,000 after buying an additional 698 shares during the last quarter.

More Arcutis Biotherapeutics News

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $34 price target on Arcutis Biotherapeutics while raising near-term EPS estimates for 2026 quarters, reinforcing the view that earnings could improve as ZORYVE sales scale. Article Title
• Positive Sentiment: Needham also reiterated its Buy rating with a $36 target, helping sentiment by signaling that analysts still see meaningful upside from current levels.
• Positive Sentiment: The company reported a $105.4 million quarterly revenue beat and highlighted strong ZORYVE momentum, including commercial growth and pipeline progress, which remains a key driver for investor enthusiasm. Article Title
• Neutral Sentiment: Arcutis announced inducement grants to 40 new hires, a routine equity compensation move that signals continued hiring but is not likely to materially change the stock’s near-term outlook. Article Title
• Neutral Sentiment: HC Wainwright’s mix of higher and lower out-year estimates suggests analysts remain constructive overall, but are still fine-tuning the longer-term earnings model. Article Title
• Negative Sentiment: Q1 EPS missed expectations, showing Arcutis is still spending heavily as it grows; that profitability gap could limit upside if investors focus on margins rather than sales growth. Article Title
• Negative Sentiment: Several insiders sold shares under pre-arranged 10b5-1 plans, which is routine, but clustered selling can still weigh on sentiment in the short term. Article Title

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.